Key result
Peri-angioplasty adjunctive tirofiban significantly reduced 30-day all-cause mortality from 6.8% to 3.2% in STEMI patients undergoing primary PCI, with survival benefits positively correlated with Killip class.
Why the study?
Studies investigating the modulators of mortality benefit conferred by peri-angioplasty glycoprotein IIb/IIIa inhibitors in STEMI were lacking.
Does peri-PCI adjunctive tirofiban reduce 30-day all-cause mortality in patients with STEMI undergoing primary PCI?
Observational (n=1,025)
No
Does peri-PCI adjunctive tirofiban reduce 30-day all-cause mortality in patients with STEMI undergoing primary PCI?
Survival benefit from peri-angioplasty tirofiban therapy for STEMI is positively correlated with Killip class and optimal in normal-weight patients, which can be guided by a novel Killip-BMI score.
Answers are grounded in this paper and cite their sources.
May support selective tirofiban use by Killip-BMI in STEMI; leaves open randomized confirmation before practice change.
BACKGROUND: Studies investigating the modulators of mortality benefit conferred by peri-angioplasty glycoprotein IIb/IIIa inhibitors in ST-elevation myocardial infarction (STEMI) are still lacking. METHODS AND RESULTS: had a significant benefit from tirofiban (adjusted HR 0.344; 95% CI 0.145-0.814; P=0.015) compared to other BMI groups. The P value for a quadratic trend was 0.012. A novel Killip-BMI score (KBS = 2.5 × Killip category - | BMI - 24 |) was calculated to select the beneficial population. A KBS ≥2 was associated with significant mortality benefit, whereas a KBS <0 predicted increased 30-day mortality with tirofiban use. CONCLUSIONS: Survival benefit from peri-angioplasty tirofiban therapy for STEMI was positively correlated with the Killip class. Tirofiban should be used cautiously in either underweight or overweight patients. The novel KBS used in this study can guide peri-angioplasty use of adjunctive tirofiban in patients with STEMI undergoing primary angioplasty.
No takes yet. Share an insight, caveat, or question.
Yeh et al. (2021) conducted an observational in ST-elevation myocardial infarction (STEMI) (n=1,025). Tirofiban vs. No tirofiban was evaluated on 30-day all-cause mortality (p=0.008). Peri-angioplasty adjunctive tirofiban significantly reduced 30-day all-cause mortality from 6.8% to 3.2% in STEMI patients undergoing primary PCI, with survival benefits positively correlated with Killip class.
Synapse has enriched 10 related papers. Consider them for comparative context: